Severe gram positive bacterial infection in an ulcerative colitis patient treated with Infliximab.
Tumour necrosis factor-alpha (TNF-α) inhibitors represent an important treatment advance for a number of inflammatory conditions, including inflammatory bowel disease. Since their introduction in 1999, it has become clear that some biological therapies may be associated with an increased risk for bacterial infections. Herein we present the first case of septic arthritis and spine empyema, caused by S. aureus, in a 63 year-old patient with ulcerative colitis, who was under treatment with Infliximab and with 40mg per day of prednisolone.
Gastroenterology Department, Hospital São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal.
M
M
Marques
S
S
Rodrigues
E
E
Mariz
J
J
Pinto
T
T
Videira
J
J
Brito
C
C
Reis
F
F
Simões-Ventura
F
F
Magro
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001170:Arthritis, Infectious / Q000209:etiology*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology*; D004653:Empyema / Q000209:etiology*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D000069285:Infliximab; D008159:Lumbar Vertebrae / Q000382:microbiology; D008875:Middle Aged; D012785:Shoulder Joint / Q000382:microbiology; D013166:Spondylitis / Q000209:etiology*; D013203:Staphylococcal Infections / Q000209:etiology*; D013211:Staphylococcus aureus / Q000302:isolation & purification; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab